SSAO/VAP-1 inhibitors (Boehringer Ingelheim)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameSSAO/VAP-1 inhibitors (Boehringer Ingelheim)
Drug Alias NameSSAO/VAP-1 inhibitors (Pharmaxis)vascular adhesion protein-1 inhibitor (Pharmaxis)membrane copper amine oxidase modulators (Pharmaxis)VAP1 inhibitor (Pharmaxis)PXS-4159 +[8] 
ClassificationSmall molecules
Mechanisms of ActionAmine oxidase, copper containing inhibitors
TargetsAmine oxidase, copper containing
Therapy Area/IndicationsAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New ZealandGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSyntara Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSyntara LtdBoehringer Ingelheim International Gmbh
Active IndicationsN/A
Inactive IndicationsAsthma

Other Information

ATC CodeN/A
Related LinksN/A